|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Wyeth |
|---|---|
| Information provided by: | Wyeth |
| ClinicalTrials.gov Identifier: | NCT00329147 |
Purpose
The purpose of this study is to evaluate the effects of multiple doses of DVS SR and paroxetine on the pharmacokinetics of a single dose of desipramine in healthy subjects.
| Condition | Intervention | Phase |
|---|---|---|
|
Depression |
Drug: desvenlafaxine SR Drug: desipramine Drug: paroxetine |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Pharmacokinetics Study |
| Official Title: | A Randomized, Open-Label, Cross-Over Drug Interaction Study to Evaluate the Effects of Desvenlafaxine (DVS SR) and Paroxetine on the Pharmacokinetics of Desipramine in Healthy Subjects |
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
More Information
| Study ID Numbers: | 3151A1-900 |
| Study First Received: | May 23, 2006 |
| Last Updated: | December 6, 2007 |
| ClinicalTrials.gov Identifier: | NCT00329147 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Healthy Subjects Major Depressive Disorder Depression |
|
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Depression Adrenergic Agents Molecular Mechanisms of Pharmacological Action Adrenergic Uptake Inhibitors Physiological Effects of Drugs Psychotropic Drugs Enzyme Inhibitors Depressive Disorder Desipramine Serotonin Uptake Inhibitors |
Paroxetine Pharmacologic Actions Behavioral Symptoms Antidepressive Agents, Tricyclic Serotonin Agents Mental Disorders O-desmethylvenlafaxine Therapeutic Uses Mood Disorders Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |